Navigation Links
Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at BioCentury's NewsMakers in the Biotech Industry Conference, being held at the Millennium Broadway Hotel and Conference Center in New York City.  Mr. Bentsur's presentation is scheduled to take place on Friday, October 22, 2010, at 2:00 p.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.com
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , February 23, 2017 ... market: the Berlin office was ... Magdalena Kritikos . The portfolio includes Entocort ® ... for the treatment of ulcerative colitis, and VistaPrep ® ... solutions, the Swiss specialty pharmaceutical company focused on the ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
(Date:2/23/2017)... 23, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ... oncology and dermatology biopharmaceutical company, today announced that it ... Rodrigues as special advisers to the Company,s Board ... the board on financial and corporate strategy. ... commitment of up to $2.5 million from Eric ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as well as ... helps transform the HCC Risk Adjustment process from a typical fragmented process ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its steady ... Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission Hills ... liability and other personal injury cases. These injuries have a major impact on ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Using the ... leads utilizing a simple online checklist. Over a period of just 24 months, thousands ... assistance of an online checklist called T.A.D. , “The internet is not getting quieter. ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Centers for ... help small practices in Delaware, New Jersey, Pennsylvania and West Virginia prepare for ... and CHIP Reauthorization Act of 2015 (MACRA). , This technical assistance, authorized ...
Breaking Medicine News(10 mins):